GLP-1 Safety: Pharmacovigilance Resources
The pharmacovigilance principles taught throughout this course - individual case safety reports, ADR surveillance, causality assessment, signal detection - apply to every drug class, not only vaccines. The resources below extend the same framework to a class where patient and clinician adverse-event reports carry disproportionate signal weight: compounded tirzepatide and semaglutide.
Compounded GLP-1 medications are not subject to the New Drug Application review, manufacturer-mandated cGMP standards, or manufacturer-driven adverse-event reporting that govern FDA-approved branded products. The pharmacovigilance burden therefore shifts to patients, clinicians, and pharmacists. Each individual MedWatch submission becomes a meaningful contribution to the only systematic feedback loop that exists for the category.
The articles below cover recognition, reporting, regulatory framework, and provider-level safety audits for compounded tirzepatide and semaglutide patients in 2026.
Resources
Start here
- Tirzepatide Side Effects: A Pharmacovigilance GuidePatient and prescriber guide to common, concerning, and serious tirzepatide adverse events, including a dose-by-dose timeline, FAQ, and provider response patterns. Cornerstone resource for the section.
- How to Verify Your GLP-1 Pharmacy Is FDA-CompliantPatient-side 4-step framework for verifying a 503A compounding pharmacy is licensed, accredited, and free of FDA enforcement actions. State-by-state license-lookup table.
- Safest Compounded Tirzepatide Providers in 20269 compounded tirzepatide telehealth providers ranked by safety, not price: 503A compliance, adverse-event response, cold-chain handling, clinical oversight, regulatory posture.
- Safest Compounded Semaglutide Pharmacies in 20268 compounded semaglutide telehealth pharmacies audited against FDA warning letters, USP <797>, state board records, and PCAB / LegitScript accreditation. Ranked by safety, not price.
- Cheapest Tirzepatide Online: 7 Safest Compounded Programs in 2026Cheapest legitimate compounded tirzepatide telehealth programs that still pass the safety audit. Pharmacy network disclosure, FDA warning-letter checks, and pricing transparency considered together.
- Cheapest Compounded Semaglutide Online in 20266 cheapest compounded semaglutide telehealth programs ranked by True Monthly Cost. Cold-chain shipping, licensed clinicians, transparent pricing, starting at $119.
- Best Online GLP-1 Programs in 2026 (Cross-Molecule)8 online GLP-1 telehealth programs audited across pricing, pharmacy network safety, medication handling, and patient support. Ranked across both compounded tirzepatide and semaglutide.
Pricing & access
- How to Get Prescribed Compounded Tirzepatide in 2026Step-by-step patient guide: BMI eligibility, the 503A personalization exception, choosing a legitimate telehealth provider, intake honesty, prescription review, pricing options, and the receive-and-inject playbook.
- Compounded Tirzepatide Cost Breakdown: What You'll Actually PayPer-milligram math, line-item first-month totals, flat-rate vs tiered pricing, microdosing as a cost lever, and the contract clauses that flip your effective cost.
Provider safety audit
- What Is 503A Compounding, and Why It Matters for TirzepatidePlain-English explainer of 21 USC § 353a (Section 503A): what the statute requires, how it differs from 503B, and how to verify your pharmacy is operating inside it.
- Are BBB Ratings Reliable for Telehealth GLP-1 Providers?How to read BBB ratings, Trustpilot scores, and Reddit threads together when vetting compounded GLP-1 telehealth providers. A 3-source triangulation framework.
- Compounded Tirzepatide and Cold-Chain Failures: A Patient Safety AuditCold-chain SOP requirements for compounded tirzepatide, the documented gap between published policy and real-world performance, and a 5-step pre-purchase audit.
- Eli Lilly v. Henry Meds: What Patients Need to KnowWhat Lilly alleges, what the September 2025 ruling actually decided, why the personalization claim is the structural fight, and how to spot the same pattern at any compounded GLP-1 provider.
Adverse event reporting
- GLP-1 Adverse Event Recognition FrameworkThree-tier triage framework for tirzepatide and semaglutide reactions: home care, same-day call, ER. Built from FDA, AGA, and ATA guidance.
- How to File a MedWatch Report on a GLP-1 (Form 3500B)Step-by-step Form 3500B walkthrough for GLP-1 adverse events, including the compounded-medication fields most patients fill incorrectly.
- Compounded GLP-1 Variability and Why Reports MatterWhy batch-to-batch variability in compounded preparations makes individual MedWatch reports the primary safety signal. Branded vs compounded quality regimes explained.
- When to Stop a GLP-1: Red Flags and Stop CriteriaFour-tier triage framework for deciding to continue, pause, or stop tirzepatide and semaglutide. Compounded-specific stop criteria included.
- Tirzepatide Side Effects Timeline: Day 1 to Long-TermPatient timeline guide: what to expect from day 1 through long-term tirzepatide use, with dose-escalation patterns and a tracking template.
- Compounded Tirzepatide With B6, B12, or NiacinamideWhat B6, B12, niacinamide, and other compound additives in tirzepatide are, why they're added, and the side effects each can cause.
Pharmacy verification
- 503A vs 503B Pharmacy: A Patient's Guide for Compounded GLP-1503A vs 503B pharmacy explained for compounded tirzepatide patients in 2026: statutes, oversight, the March 2025 503B shutdown, and how to tell which fills your Rx.
- How to Verify a Compounding Pharmacy's LicenseStep-by-step verification guide for confirming a 503A or 503B compounding pharmacy is licensed using NABP, state board, and FDA databases. State-by-state lookup table.
- PCAB, ACHC, and URAC: What These Accreditations Actually VerifyWhat PCAB, ACHC, and URAC actually inspect for compounded GLP-1 pharmacies, including audit cadence, scope, and limitations of each credential.
Why this content lives on Vaccine Safety Training
The Vaccine Safety Basics course exists to teach pharmacovigilance principles to professionals and patients across drug categories. The same individual case safety report framework, the same causality assessment criteria, and the same signal detection methodology apply whether the medication is a vaccine, a small-molecule drug, or a compounded peptide. The GLP-1 Safety resources are an applied parallel to the vaccine-focused content elsewhere on this site, written for a class of medication where the institutional safety infrastructure is thinner than it is for FDA-approved products.
For the foundational pharmacovigilance teaching that underpins these resources, see the Pharmacovigilance module and the ADR Surveillance module.